| 前收盘价格 | 159.42 |
| 收盘价格 | 162.20 |
| 成交量 | 228,293 |
| 平均成交量 (3个月) | 181,132 |
| 市值 | 6,009,093,632 |
| 预期市盈率 (P/E Forward) | 204.08 |
| 股市价格/股市净资产 (P/B) | 21.89 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -1.36 |
| 总债务/股东权益 (D/E MRQ) | 0.37% |
| 流动比率 (MRQ) | 25.98 |
| 营业现金流 (OCF TTM) | -29.23 M |
| 杠杆自由现金流 (LFCF TTM) | -13.42 M |
| 资产报酬率 (ROA TTM) | -22.23% |
| 股东权益报酬率 (ROE TTM) | -33.43% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Belite Bio, Inc | 看涨 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 53.93% |
| 机构持股比例 | 0.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Polymer Capital Management (Hk) Ltd | 30 Sep 2025 | 7,266 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 194.00 (Mizuho, 21.11%) | 购买 |
| 中 | 185.00 (15.50%) | |
| 低 | 132.00 (Benchmark, -17.59%) | 购买 |
| 平均值 | 171.20 (6.88%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 141.39 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 06 Jan 2026 | 191.00 (19.24%) | 购买 | 160.18 |
| Mizuho | 02 Dec 2025 | 194.00 (21.11%) | 购买 | 150.84 |
| 20 Nov 2025 | 105.00 (-34.45%) | 保留 | 109.18 | |
| HC Wainwright & Co. | 01 Dec 2025 | 185.00 (15.50%) | 购买 | 154.02 |
| Cantor Fitzgerald | 24 Nov 2025 | 154.00 (-3.86%) | 购买 | 136.00 |
| Benchmark | 31 Oct 2025 | 132.00 (-17.59%) | 购买 | 105.91 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合